Member Info for HedgeHogarth

H4H - I stand corrected. You are right, it does look like CBR is now the confirmed Priority number 2. I did hesitate when writing that bit and was going to say i was only 80% sure

Thanks for clarifying

HT - Don't sink to the level of the few village idiots on here....

In answer to your question, given it's so close now, I will be very happy to get a through update from Hemogenyx as part of their annual report. That is it's purpose, for most listed companies, its the vehicle to get updates. It is due no later than in 12 trading days time, failure to publish would result in suspension.

Your comment regarding the half year report is lazy IMO. The timeline for for last 9 mths looks like this

July 6th - Vlad gave a detailed CAR-T update as part of an investor webinar. (available on YouTube). He laid out the H2 timeline, very clearly and fully transparently

July 13th - HEMO moves int new premises; this was pivotal allowing Hemo to manufacture their own CAR-T. The alternative will have taken longer and been significantly more expensive. As an investor, It's reassuring that Hemo took this decision and are in control of the quality of the cells.

est. August - Clean Rooms - ISO 7 Qualification required BEFORE Hemo could commence manufacturing

est. Sept - Model CAR-T Process Run - at least 1, probably more than 1. Vlad confirmed in webinar that Hemo scientists had been in Canada working on process development with Lonza with completing in July 23.

RNS - Hemo confirmed the completion of its 2nd and final SUCCESSFUL process run on 17th November

est. Sept to Dec - Plan was to conduct a minimum of 3 CAR-T engineering runs - a core requirement for IND. Each one taking 1 month consisting of: 12 days manufacture + up to 3 weeks of testing, analytics and reporting by both Hemo and a third party to prove to FDA that they are manufactured correctly and that they successfully kill AML cancer cells.

HEMO updated the market on the completion of each test:
RNS - 12th December - Hemo confirmed the SUCCESSFUL completion of its 1st engineering qualification run.
RNS - 4th January - Hemo confirmed the SUCCESSFUL completion of its 2nd engineering qualification run.
RNS - 23rd January - Hemo confirmed the SUCCESSFUL completion of its 3rd and final engineering qualification run.
RNS - 23rd March- Hemo confirmed the SUCCESSFUL completion of the full analytical tests by the third party. This was confirmed as the FINAL manufacturing step required to submit IND.

It was clear on 12 December that the final manufacturing step ahead of IND submission, the minimum 3 PQ engineering runs, was complete and that it would be at least a further 2 months before the minimum 3 mths would be complete.

It was not 100% clear whether the dates shared in July were the estimated/targeted date range or the period in which the whole task would be completed.; e.g Sept-Dec for minimum of 3PQ runs - could mean they expected to start in that period OR whether they expected to complete the whole task in that period. Open to interpretation.

Either way, in just 8 months, HEMO completed all the manufacturing requirements to submit IND and start clinical tri

So many green boxes - so glad I have filtered out the absolute garbage that lands on this page. I imagine they are starting to panic with the RNS around the corner

Not long to go now - a maximum of 12 days to wait before we get a fully audited update from Hemogenyx.

I would normally be saying that I doubt there will be much in the report to surprise me; they have been boringly, predictable, very much following the plans they have laid out in webcasts and through RNS updates - just what investors love .

However, the timing of the report this year comes at a pivotal time. Investors are eagerly awaiting updates on all three product candidates and are also keen to understand a little more about what the addition £4m funding that #HEMO secured this year will be used for (as part of their 'post period update' and outlook section. So just his once @Hemo, I'm happy for you to spring a few surprises. :-)

I'd suggest we all lower expectations regarding a potential grant:

1 - There has been no confirmation that #HEMO have applied for a grant - a stated 'interest' in Biodefense has been shared and we have seen Vlad pictured in the room at Biodefense conference

2 - We have not yet had an update on CBR tests; assuming they are not completed yet so this may mean the 2023 Grant awards come too soon.

3 - Any grant will come with a certain expectations and conditions on how it is used. It will create a degree of commitment to Biodefense - which has an opportunity cost. If CBR continues to show the potential that it has so far, there are likely to be bigger and better commercial opportunities - which may be harder to pursue if #HEMO commit to Biodefense.

4) The grant will be linked to CBR - which is currently ranks as #HEMO's third priority; CAR-T is number one priority and CDX is further developed and regarded as number 2 priority (I'm 90% sure on the latter) . Therefore I think investors should put less importance on a Grant that may or may not have been applied for and may or may not be awarded.

We have a maximum of 12 trading days to wait for the eagerly anticipated next update from Hemogenyx

There is a good chance we may get 2; 1 (the results) is as good as guaranteed, but given the potential news/progress that is due in FY23 , it is possible we may see a separate standalone RNS as well.

GL to those invested

Stas - by the time the taxman has had his chunk, he probably sees c£150k net in take home. After mortgage and other monthly commitments etc he would not have £100k

Investing is all about buying low and selling high
With a mCap of £8m - it feels like the market expects it to fail - so I think it is fair to constitute the current price as LOW
As recently as Septmeber 2020, the mCap was £147m which was relatively HIGH vs today's mCap
At an mCap of £8m - the balance of risk / opportunity looks decent

Agree Davand.... People make mistakes, a lot less people make the same mistake twice
The argument on here is the board pumped lots of money in between 10p and 20p as well
But, contrary to what some of the board think, the board are not stupid, I think the fact they all invested so heavily at 0.3p is a very good sign here.

AIMO - GL all

As long as we land safely, we will be happy

They did invest between 7p and 18p.
After seeing that investments capitulate - would you invest another £100k?

Of course it's true: They are fine final stages - they just had to complete the three PQ runs, thye have just taken a little longer than some of those posting on here have hoped. Perhaps things took a little longer than Hemo hoped too.

Think of what cane before "final stages": years of lab tests and research, moving premises, recruitment, partnership with Penn, new more recent partnerships and prep and probably a whole lot more ups and downs.

At university, i was in my final stage (it lasted about a year)

Currently talks are ongoing between my company and Vodafone, "final discussion" before agreement of whether to create a UK single entity. We expected an update in December, Its now April and we are still waiting - but it does not make a huge difference in the grand scheme of things. Both copanies expected to update before Xmas, but it did not happen, does not mean they cannot be trusted or were not honest!

Get a grip of yourself Pumpky and grow up

The board have invested a lot of their own children's inheritance at 0.3p....
That tom me suggests that 0.27p is a great entry point
mCap now just £8m - yet this company is a professional outfit and has some strong assets.
Lets hope the next update is positive and we can start to see some recovery in the value of this company

Pumpky - agree with all of what you say in last post expect the last bit.

Hence, why your contributions are so UNPOPULAR - we are all trying to make money yet your posts constantly create doubt and negativity.

You may be right that companies are not always as honest as we'd like. But I DO trust HEMO, if i did not I can categorically assure you that i would NOT be invested.

I have no reason to believe that anything HEMO have ever put in an RNS is not what they believed to be true at the time of writing it.

All companies, including the one I work for, will try and put a positive spin, where possible, when things don't work out the way they hoped. We live in a world where employees and shareholders do not like to think their CEO can get things wrong occasionally - so CEOs all the world over will always try and avoid admitting to a mistake - and when they do they may celebrate it as a great decision to "fail fast".

There are also many reasons and occasions when public limited companies withhold information where it is legal to do so; this could be due to (1) an NDA, (2) wanting to mitigate an issue before it becomes public knowledge or (3) its at an early stage and only speculative

This is very different to not trusting what a company says. Of course there are companies that are shown to have been untruthful and untrustworthy - unless i have missed something or something big happened before my time, I can hand on heart say that HEMO have done nothing to suggest they cannot be trusted.

(There were open and honest about the CLNs - people may not have liked them but that was the funding route that Hemo chose as best for them at the time)

Just my opinion guys - I would suggest you don't invest if you do not trust Hemo.

Pretty sure from memory, that is the way things started early Jan before the more interesting gains.

Looks like we are on target for 3rd blue day on the trot...
#justsaying
That is the sort of thing that excites chart types...

What a great idea"
Pumpky is like one of those smart alec kids - they think they are being clever and funny but they are not
We also know that Pumpky intentionally brings a negative slant to EVERY post they make
Pumpky also gets things wrong regularly - just this week alone they (a) confused a buy with a sell because it was blue and today suggesting 2022/3 would be a tax loss - yet the SP went +26.67% in that tax year
Grade A Plum

pumpky wrong as ever, just looked at a dummy sell and was offered 2.06p

L200 - blue is blue whether 1% or 10% - 5 blue days of 1% will do me for starters

The last time we have some momentum - I think it was 5 or more blue days on the trot was the first week of January. Another blue day today would be great

H4H - your post echos very much the same as mine with the exception that you have a more negative slant on Vlad and seem less trusting for some reason of their updates.

I don't understand this obsession for news and the accusation that Vlad runs as a private company; as other posted have written, we have had a number of updates this year already; 1 on CBR and 1 on CAR-T. This is Biotech, there is not going to be news every week/month to release.

My experience of the few companies that release the most news are usually doing it to ramp up the share price and as a result the SP tends to be volatile - take a look at Tiziana.

Big companies don't release any more news than Hemo. WIth all listed companies, we know that as a minimum, we will get two comprehensive, audited updates twice a year.

We just have to be patient and give Hemo a chance to deliver what we all hope they can